阿司匹林用于恶性远端胆总管梗阻金属支架(AIMS)的多中心随机对照试验研究方案
本研究为研究者发起的多中心双盲随机安慰剂对照试验,计划在韩国四家三级中心纳入184例恶性远端胆总管梗阻且成功接受内镜下金属支架置入的成人患者,随机分为每日100 mg阿司匹林组与安慰剂组,用药6个月,主要结局为支架功能障碍发生率,次要结局包括支架通畅时间、再干预率和不良事件。
要点
- 探讨阿司匹林能否延长恶性远端胆总管梗阻患者金属支架的通畅时间。
- 设计为多中心双盲随机安慰剂对照试验,计划样本量184例。
- 主要结局为支架功能障碍发生率,次要结局含通畅时间与再干预率。
核心结论
- AIMS研究旨在确定阿司匹林在维持恶性远端胆总管梗阻患者金属支架通畅性方面的疗效。
研究设计与样本
- 计划纳入184例年龄≥20岁、恶性远端胆总管梗阻且内镜下金属支架置入成功的成人患者。
- 患者随机分为两组,分别在接受索引ERBD后服用100 mg阿司匹林或安慰剂6个月。
关键数值与推荐
- 主要结局为支架功能障碍发生率。
- 次要结局包括支架通畅时间、再干预率及不良事件发生率。
- 干预为阿司匹林100 mg或安慰剂,疗程6个月。
- 试验注册号ClinicalTrials.gov NCT03279809,注册日期2017年9月5日。
临床怎么用
- 若研究证实有效,阿司匹林可能成为延长恶性远端胆总管梗阻患者金属支架通畅时间的简便辅助用药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endoscopic retrograde biliary drainage (ERBD) is the treatment of choice for patients with malignant distal common bile duct (CBD) obstruction. Self-expandable metal stents (SEMS), which are commonly used in unresectable cases, have many clinical advantages, including longer stent patency. Although the expected patency of SEMS is around 8 months, it has recently been reported that the duration of SEMS' patency in patients using aspirin is prolonged. Our study, therefore, aims to investigate the effect of aspirin on SEMS' patency. METHODS/DESIGN: This is an investigator-initiated, prospective, multicenter, double-blind, randomized placebo-controlled trial that will be conducted from November 2017 in four tertiary centers in South Korea. We intend to include in our study 184 adult (aged ≥ 20 years) patients with malignant distal CBD obstruction for whom ERBD with SEMS was successfully performed. The patients will be randomly allocated to two groups, which will comprise patients who have either taken 100 mg aspirin or a placebo for 6 months after index ERBD. The primary outcome will be the rate of stent dysfunction, and the secondary outcomes will be the duration of patency, the rate of reintervention, and the occurrence of adverse events. DISCUSSION: The aspirin for metal stents in malignant distal common bile duct obstruction (AIMS) study should determine the efficacy of aspirin in maintaining metal-stent patency in patients with malignant distal CBD obstructive. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03279809. Registered on 5 September 2017.
引用
- Choi JH, Paik WH, You MS, et al. Aspirin for metal stent in malignant distal common bile duct obstruction (AIMS): study protocol for a multicenter randomized controlled trial. Trials. 2020. PMID: 32000828. doi:10.1186/s13063-020-4083-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。